Nonetheless, the sensitization ofTRAIL-induced death by PPARγ agonists may have relevant clinicalimplications as TRAIL is currently being tested in clinical trials for cancer.Identification of tumors that can overcome TRAIL resistance by treatment withPPARγ agonists will enhance tumor specific targetingby TRAIL and reduce toxicity of normal tissues as TRAIL has been shown toinduce death in tumor cells while sparing normal cells. This evidence concerns the gene PPARG and neoplasm.